ClinicalTrials.gg
CompletedNCT02242344Updated Dec 28, 2017

Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension

A Phase 2 interventional study of Telmisartan and Placebo in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-12-28.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
67th of 99
77 · median 184
Started
2006
with 9 others
Phase 2
4 of 99
none open now
Registered
69th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 67th largest by enrollment, is one of 10 that started in 2006, is one of 4 in phase 2, and was the 69th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

Study to assess the blood pressure lowering effects of two doses of telmisartan over a four-week treatment period; to determine potentially effective doses for pediatric patients for future studies; to assess the safety and tolerability of two doses of telmisartan.

Pharmacokinetic objectives included the determination of the steady-state pharmacokinetics of telmisartan in children and adolescents aged 6 to \<18 years, and to determine if age-related differences exist

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female children and adolescents 6 to \<18 years of age at time of /assent
  2. Ability to provide written informed consent in accordance with Good Clinical Practice (GCP) and local Institutional Review Boards (IRBs), and/or patient assent, when appropriate
  3. Ability to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigator's discretion)
  4. Weight ≥20 kg and ≤120 kg
  5. Hypertensive patients: in-clinic seated SBP ≥ 95th percentile based on age, height, and gender as defined in The Fourth Report on the Diagnosis, Evaluation and Treatment of High Blood Pressure in Children and Adolescents
  6. Ability to swallow whole tablets

Exclusion criteria

Exclusion Criteria:

  1. Hypertension accompanied by symptoms or signs of central nervous system injury, including stroke, seizures, or encephalopathy, within 6 months prior to enrollment in the study
  2. Children whose in-clinic seated BP measurements are 20 mmHg SBP or 10 mmHg DBP above the 95th percentile based on The Fourth Report on the Diagnosis, Evaluation and Treatment of High Blood Pressure in Children and Adolescents
  3. Bilateral renal artery stenosis, unilateral renal artery stenosis in a solitary kidney, or uncorrected coarctation of the aorta
  4. Congestive heart failure, valvular disease, or cardiac rhythm disturbances
  5. Bone marrow transplantation
  6. Solid organ transplantation
  7. Stroke
  8. Chronic Kidney Disease with (GFR) to \< 40 ml/min/1.73m2 by the Schwartz formula:

    Estimated GFR = (k x Height [cm]/ Serum Creatinine (mg/dL). k = 0.55 for all females and boys \<13 years old; k = 0.7 in adolescent males ≥13 years old)

  9. Clinically significant hepatic disease or abnormal liver function tests:

    1. Serum Glutamate-Oxaloacetate-Transaminase () (SGOT), Serum Glutamate-Pyruvate-Transaminase (Alanine Aminotransferase) (SGPT), or Gamma-Glutamyl-Transferase (GGT) more than 2x
    2. Total or direct more than 1.5x upper limit of normal
  10. Clinically significant gastrointestinal disease that may affect drug absorption or excretion (including gastroesophageal reflux, malabsorption, biliary disease, pancreatic disease)
  11. Hyponatremia (serum sodium ≤130 mEq/L), hyperkalemia (Serum potassium ≥ 5.5 mEq/L), or other clinically significant electrolyte disorders
  12. Significant hypoalbuminemia (serum albumin ≤2.5 g/dL)
  13. Clinically significant neurological, psychiatric, pulmonary, hematological, or other condition that, in the opinion of the Investigator, will interfere with the safe and successful completion of the study
  14. to angiotensin II receptor antagonists
  15. Females who are of who:

    1. are pregnant/have a positive urine pregnancy test (UPT) prior to randomization (Visit 2), or
    2. are nursing, or lactating, or
    3. would not confirm abstinence (patients must be abstinent throughout the duration of the trial), or
    4. are not currently practicing one of the acceptable methods of . Acceptable methods of birth control are limited to: Intra-Uterine Device (IUD), oral, implantable or injectable contraceptives and estrogen patch.
  16. Concomitant therapy with any of the following agents:

    • Any angiotensin II receptor antagonist within four (4) weeks prior to randomization into the study
    • Any medication that could affect BP
    • Angiotensin Converting Enzyme (ACE) inhibitors within four (4) weeks prior to randomization into the study
    • Intravenous pulse therapy within one month, daily treatment with oral corticosteroids ≥1 mg/kg/day)
    • Anticonvulsant medications
    • Bile acid binding agents
    • Any drug that may interfere with absorption of the study medication (e.g.antacids)
    • Drugs that may affect gastrointestinal motility (e.g. metoclopramide)
    • Cytotoxic agents within 12 months prior to enrollment into the study
  17. Other drugs or treatments within 30 days prior to enrollment
  18. Patients who require two or more anti-hypertensive medications
  19. Hereditary fructose intolerance
  20. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
77 participants (actual)

Study arms

  • Experimental
    telmisartan - low dose

    Drug: Telmisartan

  • Experimental
    telmisartan - high dose

    Drug: Telmisartan

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in seated systolic blood pressure (SBP)

    Time frame: Baseline, after 4 weeks of treatment

Secondary outcomes

  1. Change from baseline in seated diastolic blood pressure (DBP)

    Time frame: Baseline, after 4 weeks of treatment

  2. Response rate of blood pressure

    defined as both SBP and DBP \< 95th percentile at the patient's final visit based on age, height, and gender

    Time frame: after 4 weeks

  3. Cmax,ss (maximum concentration of the analyte in plasma at steady state over a uniform dosing interval)

    Time frame: 72 hours after last study drug administration

  4. Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval)

    Time frame: 72 hours after last study drug administration

  5. Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)

    Time frame: 72 hours after last study drug administration

  6. Cavg (Average concentration of the analyte in plasma at steady state)

    Time frame: 72 hours after last study drug administration

  7. tmax,ss (time from dosing to maximum concentration at steady state)

    Time frame: 72 hours after last study drug administration

  8. AUCτ,ss (area under the concentration time curve of the analyte in plasma at steady state over a uniform dosing interval)

    Time frame: 72 hours after last study drug administration

  9. t1/2,ss (terminal half-life of the analyte in plasma at steady state)

    Time frame: 72 hours after last study drug administration

  10. MRTpo,ss (mean residence time of the analyte in the body at steady state)

    Time frame: 72 hours after last study drug administration

  11. CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)

    Time frame: 72 hours after last study drug administration

  12. Vz/F,ss (apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state)

    Time frame: 72 hours after last study drug administration

  13. PTF (peak trough fluctuation)

    Time frame: 72 hours after last study drug administration

  14. Number of patients with adverse events

    Time frame: up to 45 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006 and a primary completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2014
First posted
Sep 17, 2014
Start
Apr 2006
Primary completionActual
Sep 2007
Last update
Dec 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02242344
Responsible party
Sponsor
First posted
Sep 17, 2014
Start date
Apr 2006
Primary completion
Sep 2007
Last update
Dec 28, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion